Plitidepsin

Plitidepsin (Aplidin) is an anticancer drug that belongs to a class of drugs known as peptidase inhibitors. It is used to treat certain types of cancer such as multiple myeloma, a type of blood cancer. Plitidepsin works by interfering with the growth and spread of cancer cells. It also helps to reduce the size of tumors. This medicine is given intravenously (IV) or by intramuscular injection (IM). Common side effects of this medication include fatigue, anemia, nausea, vomiting, and headache.

Plitidepsin is a compound with interesting properties, currently being investigated for its potential against COVID-19. Here's a breakdown of what we know about it:

• Source: Plitidepsin is a cyclic depsipeptide, meaning it's a molecule derived from a marine invertebrate called Aplidium albicans [1].
• Original Use: It was initially studied for its anti-tumor properties, showing promise in fighting multiple myeloma [2].
• Mechanism of Action: Plitidepsin works by inhibiting a protein in human cells called eukaryotic translation elongation factor 1A (eEF1A) [2]. This disrupts cancer cell growth but may also hinder the replication of the SARS-CoV-2 virus [3].
• COVID-19 Potential: Early research suggests plitidepsin might be effective against COVID-19. It's shown promise in lab studies and early clinical trials are underway to assess its safety and efficacy for this purpose [3, 6].
• Current Status: Plitidepsin is not a widely used medication yet. It has limited approval in Australia for multiple myeloma and is undergoing clinical trials to determine its effectiveness against COVID-19 [8].

Important Points to Remember:

• Plitidepsin is still under investigation for COVID-19 treatment, and more studies are needed.
• It's not a substitute for established COVID-19 protocols and should only be used under medical supervision within a clinical trial setting.